DUBLIN, Aug. 28, 2020 /PRNewswire/ -- The "Radiation Induced Esophagitis Market Insights, Epidemiology, and Market Forecast - 2030" drug pipelines has been added to ResearchAndMarkets.com's offering.
This report, delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of radiation-induced esophagitis (RIE) in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
The market report provides analysis regarding current treatment practices, emerging drugs like GC4419, potential therapies, market share of the individual therapies, and historical, current and forecasted RIE market size from 2017 to 2030, segmented by seven major markets.
The report also covers current radiation-induced esophagitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Epidemiology
The radiation-induced esophagitis (RIE) epidemiology chapters provide insights about historical and current RIE patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. RIE epidemiology is segmented by the incidence of lung cancer by types, the stage-wise incidence of NSCLC, cases receiving CCRT/CRT, acute radiation-induced esophagitis (ARIE) by grade. Besides, the report includes a thorough analysis of all segments.
Radiation-induced esophagitis can be divided into two subtypes using a grading system are namely: acute and late. In the US, the cases of RIE were found to be 7,834 for grade 4, 926 for grade1, 8,508 for grade 2, 2,463 for grade 3, and 226 for grade 4, in 2017.
According to the report, the total prevalent population of RIE in seven major markets was 57,455 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017-2030).
Among all the seven major markets, the United States accounted for the highest number of radiation-induced esophagitis cases.
Drug Chapters
This segment encloses the detailed analysis of the drugs in the radiation-induced esophagitis (RIE) pipeline. It also helps to understand the RIE clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.
Treatment is supportive care with adequate hydration and nutrition intake. Amifostine, an organic triphosphate, has been studied and shown to act as a radioprotector. Dietary modifications are also suggested. Moreover, Galera Therapeutics' GC4419 is the only therapy in the pipeline.
Market Outlook
The market size of radiation-induced esophagitis (RIE) is expected to increase at a significant CAGR during the study period (2017-2030). Among all the seven major markets, the United States accounted for the largest RIE market size. Among EU5 countries, Germany had the highest market size, with USD 3.22 million in 2017, while Spain had the smallest market size of RIE, with USD 1.89 million in 2017.
Drugs Uptake
This section focuses on the rate of uptake of the potential drugs in the radiation-induced esophagitis (RIE) market or expected to get launched in the market during the study period 2017-2030. The analysis covers RIE market uptake by drugs; patient uptake by therapies; and sale of each drug.
It helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size. All of which will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The dynamics of RIE market is anticipated to experience a positive shift in the coming years owing to the expected launch of GC-4419 (Galera Therapeutics).
Pipeline Activities
The report provides insights into different therapeutic candidates and also analyses the key players involved in developing targeted therapeutics.
Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing, patent details, and emerging therapies, concerning radiation-induced esophagitis.
KOL- Views
To keep up with current market trends, we take KOLs and SME's opinion working in radiation-induced esophagitis domain through primary research to fill the data gaps and validate our secondary research. It will support the clients in assessing potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We have performed the competitive and market Intelligence analysis of the radiation-induced esophagitis Market by using various competitive intelligence tools that include SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies etc. Besides, the inclusion of the analysis entirely depends upon the data availability.
Report Highlights
- In the coming years, radiation-induced esophagitis market scenario is not expected to alter much across the 7MM due to lack of approved treatment options and a static pipeline. Lack of adequate research and development activities funded by major pharma players is also making an impact on the overall landscape.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/j02p0t
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
